Advertisement


Nirav N. Shah, MD, on DLBCL: New Data on Split-Dose R-CHOP for Older Patients

2023 ASCO Annual Meeting

Advertisement

Nirav N. Shah, MD, of the Medical College of Wisconsin, discusses phase II results showing that split-dose R-CHOP offers older patients with diffuse large B-cell lymphoma (DLBCL) an equivalent dose intensity as R-CHOP-21 through a fractionated dosing schedule, improving tolerability. At the end of treatment for these older patients, a complete response rate of 71% was comparable to outcomes with R-CHOP in younger patients with the disease (Abstract 7554).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The optimal management of older patients with DLBCL remains unclear and is very variable from practice to practice. The most commonly used regimen for older patients with diffuse large B-cell lymphoma is a regimen called R-mini-CHOP, which is more or less a 50% dose reduction in the cumulative chemotherapy compared to a younger patient who gets R-CHOP21. At our institution, we have developed a regimen called split-dose R-CHOP, which basically fractionates R-CHOP21 into two half doses with full-dose rituximab given on day one, and a 50% dose reduction of the CHOP regimen on day one and day 15, so that a 28-day cycle of split-dose R-CHOP gave the same chemo cumulative dose of chemotherapy as R-CHOP21. We designed this study as a way to deliver the same dose intensity to older patients, but by fractionating it, making it more tolerable to a patient population that's at higher risk of the toxicities associated with chemotherapy. In addition, because older patients could benefit from a truncated chemotherapy regimen, we included an interim analysis of patients, where we looked at them using PET-CT and MRD, using a cell-free DNA assay- [inaudible 00:01:33]- ... to look at the depth of response after two months of split-dose R-CHOP. For those patients who are both MRD-negative and, by Deauville criteria, a PET score of one, two, or three, those patients were then offered an abbreviated chemotherapy arm where they would finish after four months of split-dose R-CHOP instead of six months. Here, we are presenting our interim feasibility endpoint, which was based on the end-of-treatment CR rate. We're reporting data on 14 patients who have completed treatment, and our end-of-CR rate with 71%, meeting our interim feasibility endpoint early with 10 of the 14 patients achieving a complete remission. Overall, this regimen was well-tolerated. There were adverse events as described in the data that we've shown, but some of these are to be expected treating an older patient population, but there were no treatment-related deaths directly related to the chemotherapy. The most interesting aspect of this data was, however, that analysis we did using PET-CT and MRD. For six patients, who were both MRD-negative and PET-CT-negative, five of the six went onto the abbreviated arm. Even though they finished this truncated regimen, all of them remained in remission to-date. This shows that there might be power in this early-responding group that have a high in-depth- [inaudible 00:03:03]- ... response of this early interim analysis. We look forward to sharing this data at ASCO, and continuing to enroll patients, but we think that this could become a paradigm on how to treat older patients with DLBCL using novel endpoints, while offering a regimen with the same dose intensity that we offer younger patients to improve efficacy.

Related Videos

Breast Cancer

Lisa A. Carey, MD, and Javier Cortes, MD, PhD, on HER2-Positive Early Breast Cancer: Chemotherapy De-escalation Under Study in PHERGain Trial

Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill, and Javier Cortes, MD, PhD, of the International Breast Cancer Center and Universidad Europea de Madrid, discuss phase II findings showing that one in three patients with HER2-positive early breast cancer may safely omit chemotherapy. Among the chemotherapy-free patients treated with trastuzumab and pertuzumab, the 3-year invasive disease–free survival was 98.8%, with no distant metastases (Abstract LBA506).

Lymphoma

Tycel J. Phillips, MD, and Alex F. Herrera, MD, on DLBCL: New Data on ctDNA Status and Clinical Outcomes

Tycel J. Phillips, MD, and Alex F. Herrera, MD, both of the City of Hope National Medical Center, discuss findings from the POLARIX study, which provided the largest prospectively collected circulating tumor DNA (ctDNA) data set on patients with previously untreated diffuse large B-cell lymphoma. Achieving ctDNA-negative status was associated with improved outcomes when patients were treated with polatuzumab vedotin-piiq plus combination chemotherapy vs combination chemotherapy alone (Abstract 7523).

Bladder Cancer
Immunotherapy

Shilpa Gupta, MD, on Urothelial Carcinoma: Long-Term Outcome of Enfortumab Vedotin Plus Pembrolizumab

Shilpa Gupta, MD, of Cleveland Clinic, discusses the results from the EV-103 study and the unmet need for effective first-line therapies in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. After nearly 4 years of follow-up, the trial findings showed that enfortumab vedotin-ejfv plus pembrolizumab continues to demonstrate promising survival trends with rapid and durable responses in this population (Abstract 4505).

Colorectal Cancer

Sebastian Stintzing, MD, on Colorectal Cancer: Influence of Liquid Biopsy in First-Line Combination Treatment

Sebastian Stintzing, MD, of the Charité Universitätsmedizin Berlin, discusses results from the phase III FIRE-4 study, which showed that liquid biopsy is clinically relevant in verifying mutational status in patients with metastatic colorectal cancer and is efficacious in first-line treatment of FOLFIRI and cetuximab for patients with RAS wild-type disease (Abstract 3507).

Lymphoma

Catherine C. Coombs, MD, on B-Cell Malignancies and Long-Term Safety of Pirtobrutinib

Catherine C. Coombs, MD, of the University of California, Irvine, discusses prolonged pirtobrutinib therapy, which continues to demonstrate a safety profile amenable to long-term administration at the recommended dose without evidence of new or worsening toxicity signals. The safety and tolerability observed in patients on therapy for 12 months or more were similar to previously published safety analyses of all patients enrolled, regardless of follow-up (Abstract 7513).

Advertisement

Advertisement




Advertisement